Skip to content

Coherus partnership likely in 2H: Citi

May 18, 2017

Citi analyst, Mohit Bansal, reiterated his Buy rating on shares of Coherus Biosciences (NASDAQ: CHRS) and sees $4-$8/sh upside for the company due to PTAB’s decision in favor of CHRS in the Humira ‘135 patent IPR case.

The analyst believes this win makes Humira’s biosimilar launch based on the company’s technology is more likely since the ‘135 patent was the key patent in Humira’s patent defense.

The next key catalyst for the company is the BSUFA decision on the Neulasta biosimilar by June 9, 2017. The analyst sees the stock trading close his target price of $38/sh.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: